Literature DB >> 34480681

High serum complement component C4 as a unique predictor of unfavorable outcomes in diabetic stroke.

Ximeng Zhang1, Jun Yin2, Kai Shao1, Le Yang3, Wei Liu1,4, Yiqing Wang1, Shanshan Diao1, Shicun Huang1, Qun Xue1, Jianqiang Ni5, Yi Yang6.   

Abstract

Previous studies demonstrated that diabetic stroke patients had a poor prognosis and excess complement system activation in the peripheral blood. In this study, the association of serum complement levels with the prognosis of diabetic stroke was examined. Patients with acute ischemic stroke were recruited and were divided into two groups according to their history of diabetes. Baseline data on the admission, including C3 and C4 were collected. Neurologic function at discharge was the primary outcome and was quantified by the National Institutes of Health Stroke Scale (NIHSS). A total of 426 patients with acute ischemic stroke (116 diabetic strokes and 310 non-diabetic strokes) were recruited in this study. There were significant differences between the two groups in hypertension, coronary disease, triglyceride, high-density lipoprotein cholesterol, fasting blood sugar, C4, and mortality rates. Furthermore, the values of complement protein levels were divided into tertiles. In the diabetic stroke group, serum C4 level at the acute phase in the upper third was independently associated with NIHSS score at discharge and concurrent infection. These associations were not significant in non-diabetic stroke. High serum C4 level at admission, as a unique significant predictor, was associated with unfavorable clinical outcomes in the diabetic stroke, independently of traditional risk factors.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  C4; Complement system; Diabetes mellitus; Ischemic stroke; Outcome

Mesh:

Year:  2021        PMID: 34480681     DOI: 10.1007/s11011-021-00834-0

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  37 in total

Review 1.  Complement Components, C3 and C4, and the Metabolic Syndrome.

Authors:  Melanie Copenhaver; Chack-Yung Yu; Robert P Hoffman
Journal:  Curr Diabetes Rev       Date:  2019

2.  Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.

Authors:  Gunnar Engström; Bo Hedblad; Karl-Fredrik Eriksson; Lars Janzon; Folke Lindgärde
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

3.  Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke.

Authors:  Alvaro Cervera; Anna M Planas; Carles Justicia; Xabier Urra; Jens C Jensenius; Ferran Torres; Francisco Lozano; Angel Chamorro
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

4.  Changes in plasma levels of complement in patients with acute ischemic stroke.

Authors:  Inimioara Mihaela Cojocaru; M Cojocaru; R Tănăsescu; Cecilia Burcin; Adina Nicoleta Atanasiu; Ana-Maria Petrescu; Andreea Cristina Mitu; Iulia Iliescu; Laura Dumitrescu
Journal:  Rom J Intern Med       Date:  2008

5.  Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography.

Authors:  Erdal Cavusoglu; Calvin Eng; Vineet Chopra; Cyril Ruwende; Sunitha Yanamadala; Luther T Clark; David J Pinsky; Jonathan D Marmur
Journal:  Am J Cardiol       Date:  2007-06-04       Impact factor: 2.778

6.  Complement C3 Associates With Incidence of Diabetes, but No Evidence of a Causal Relationship.

Authors:  Yan Borné; Iram Faqir Muhammad; Laura Lorés-Motta; Bo Hedblad; Peter M Nilsson; Olle Melander; Eiko K de Jong; Anna M Blom; Anneke I den Hollander; Gunnar Engström
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

7.  Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement.

Authors:  Ali Alawieh; Andrew Elvington; Hong Zhu; Jin Yu; Mark S Kindy; Carl Atkinson; Stephen Tomlinson
Journal:  J Neuroinflammation       Date:  2015-12-30       Impact factor: 8.322

Review 8.  Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Authors:  Sarah M Carpanini; Megan Torvell; Bryan Paul Morgan
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

Review 9.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

10.  Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the 'common soil' hypothesis.

Authors:  Xue Bao; Yan Borné; Linda Johnson; Iram Faqir Muhammad; Margaretha Persson; Kaijun Niu; Gunnar Engström
Journal:  Cardiovasc Diabetol       Date:  2018-06-12       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.